ArticleDiabetes, obesity & metabolism2025
Improvement in body mass index category was associated with improved cardiometabolic measures and patient-reported outcomes in adults with type 2 diabetes treated with tirzepatide.
Article in Diabetes, obesity & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Effects of SGLT2 Inhibitors on Muscle Health in Older Adults: A Systematic Review and Meta-Analysis.Pharmacology research & perspectives · 2026Pooled it
- Shifts in body mass index category with tirzepatide and associated changes in cardiometabolic risk factors in people with obesity: a post hoc analysis from the SURMOUNT-1 and SURMOUNT-4 trials.American journal of preventive cardiology · 2026Article
- Crossing the line: BMI category changes with tirzepatide.American journal of preventive cardiology · 2026Article
- Improvement in body mass index category was associated with improved cardiometabolic measures and patient-reported outcomes in adults with type 2 diabetes treated with tirzepatide.Diabetes, obesity & metabolism · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
aimsTo estimate body mass index (BMI) category changes after treatment with tirzepatide as well as potential associations between shifting BMI category and selected cardiometabolic measures and weight-related patient-reported outcomes (PROs) in type 2 diabetes. MATERIALS AND
methodsThis post-hoc analysis analysed data from the SURPASS-1 to -5 trials for weekly tirzepatide (pooled doses) in adults with type 2 diabetes. Changes in BMI category from baseline to Week 40 or 52 (primary endpoint) were assessed and grouped into 'improved' (shift to ≥1 lower category) and 'not improved' (which included 'not improved: stable' [no change in category] or 'not improved: worsened' [shift to ≥1 higher category]). BMI categories were <25 kg/m
resultsOverall, 58.9% of 3559 participants treated with tirzepatide shifted to an 'improved' BMI category, and 41.1% were in the 'not improved' BMI category. Participants with an 'improved' versus 'not improved' BMI category had numerically larger mean improvements from baseline in the majority of the selected cardiometabolic parameters at endpoint in all five SURPASS trials. Improvements in weight-related PROs were numerically largest for participants whose BMI category 'improved'.
conclusionsAfter tirzepatide treatment, approximately 60% of adults with type 2 diabetes shifted to a lower 'improved' BMI category. This shift was generally associated with numerical improvements in selected cardiometabolic measures and weight-related PROs that may reduce cardiometabolic risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.